Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study

Toshio Shimizu 1 2, Kazuhiko Nakagawa 3, Hidetoshi Hayashi 3, Tsutomu Iwasa 3, Hisato Kawakami 3, Satomi Watanabe 3, Noboru Yamamoto 4, Kan Yonemori 4, Takafumi Koyama 4, Jun Sato 4, Kenji Tamura 4 5, Keiichi Kikuchi 6, Kenichiro Akaike 6, Shiho Takeda 6, Masayuki Takeda 3 7 1Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, Japan. sentants@wakayama-med.ac.jp. 2Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Graduate School of Medicine, Wakayama Medical University Hospital, 811-1 Kimiidera, Wakayama-City, Wakayama, Japan. sentants@wakayama-med.ac.jp. 3Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2, Osakasayama-city, Osaka, Japan. 4Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, Japan. 5Innovative Cancer Center / Department of Medical Oncology, Faculty of Medicine, Shimane University, 89-1. Enyacho Izumo-city, Shimane, Japan. 6SymBio Pharmaceuticals Limited, 3-2-2 Toranomon, Minato-ku, Tokyo, Japan. 7Department of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, Japan.

Tamura, Kenji